Evidence map›Paper›PMID 41472727›Full record

ReviewFrontiers in immunology2025

Frontiers in thoracic oncology: new breakthroughs in molecular targets and immunotherapy.

Yujing Yang, Dan Pu, Xuehan Li

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yujing Yang *Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
Dan Pu *Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Xuehan LiDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thoracic tumors, including lung cancer, breast cancer, and thymoma, usually present poor outcomes. The current treatment methods for thoracic tumors have low efficacy and are associated with severe adverse reactions. Molecular targeted therapy and immunotherapy offer new possibilities for the treatment of thoracic tumors. In this review, we have summarized the latest research on these novel therapeutic strategies, and discussed their clinical applications, challenges, and possible countermeasures. This review offers a theoretical basis for improving the outcomes of thoracic tumor patients, along with future research prospects.

Indexed as

ImmunotherapyMolecular Targeted TherapyThoracic NeoplasmsAnimalsHumansLung Neoplasmsimmune cell communicationimmunotherapymolecular targeted therapythoracic tumorstreatment progress

Identifiers

PMID41472727
PMCPMC12745259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.